Exploratory Phase 2a study showed consistent and clinically meaningful functional improvements across muscle strength, motor performance, and patient-reported outcomes in patients with Charcot-Marie-T ...
Zacks Investment Research on MSN
Ultragenyx Pharmaceutical resubmits UX111 BLA for Sanfilippo syndrome
Ultragenyx Pharmaceutical RARE announced the resubmission of its biologics license application (“BLA”) to the FDA seeking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results